The economic aspects of hepatitis C-- implications for haemophilia

Haemophilia. 1999 Nov;5(6):402-9. doi: 10.1046/j.1365-2516.1999.00363.x.

Abstract

This paper considers the literature relating to the course of hepatitis C infection and its implications for those with haemophilia. It goes on to discuss a model that assessed the economic aspects of treating hepatitis C cases with interferon-alpha, discusses recent changes in recommended treatment of hepatitis C and critically reviews the model and its application to patients with haemophilia.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Cohort Studies
  • Disease Progression
  • Female
  • Fibrosis / etiology
  • Health Care Costs
  • Hemophilia A / economics*
  • Hemophilia A / virology
  • Hepatitis C / complications
  • Hepatitis C / drug therapy*
  • Hepatitis C / economics*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / economics
  • Interferon-alpha / therapeutic use
  • Male
  • Models, Biological
  • Quality of Life
  • Recombinant Proteins
  • Survival Rate

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins